Bullish & Foolish
Full IMDX fundamentals All 466 on the Survival Watch

IMDXInsight Molecular Diagnostics Inc.

Is Insight Molecular Diagnostics struggling financially?

Yes, by its own account. Insight Molecular Diagnostics told the SEC on 13 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Sector
Biotech/Pharma
Market cap
$142.0M
Source filing
10-Q 13 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 3months

    If the burn speeds up

    Empty by Sep 2026

  • 5months

    If it eases off

    Empty by Nov 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$17.8M

÷

Cash burned over the last 12 months

$51.9M

What Insight Molecular Diagnostics told the SEC

…such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern within one year after the date that such financial statements are issued. In performing this analysis, we excluded certain elements of our operating plan that cannot be considered…

Insight Molecular Diagnostics Inc., Form 10-Q, filed 13 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 23.4% share-count increase The company issued stock. Each share now owns 19.0% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 30% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt